[Tus-Holdings Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Tus-Holdings%20Pharmaceutical%20Group%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) [I. Expected Performance for the Current Period](index=1&type=section&id=I.%20Expected%20Performance%20for%20the%20Current%20Period) The company anticipates continued losses in the first half of 2025, with net loss attributable to shareholders expected to narrow from **23.3946 million yuan** in the prior year to **15 million - 19 million yuan**, indicating a reduced loss margin Performance Forecast for the Current Period | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company (yuan)** | Loss: **15,000,000 - 19,000,000** | Loss: **23,394,600** | | **Net Profit After Deducting Non-Recurring Gains and Losses (yuan)** | Loss: **20,000,000 - 25,000,000** | Loss: **24,389,000** | | **Basic Earnings Per Share (yuan/share)** | Loss: **0.0626 - 0.0793** | Loss: **0.0977** | [II. Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The financial data in this performance forecast represents the company's preliminary estimates and has not been audited by an accounting firm - The financial data in this performance forecast is a preliminary estimate and has not been audited by an accounting firm[3](index=3&type=chunk) [III. Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) The company attributes the continued losses in the first half to two core factors: a decline in total operating revenue due to market conditions and increased raw material prices compressing overall gross margin - The company attributes the net profit loss to a decline in total operating revenue caused by market conditions over the past two years[4](index=4&type=chunk) - Rising prices of some raw and auxiliary materials are another reason for the decline in overall gross margin and profitability[4](index=4&type=chunk) [IV. Risk Warning and Other Related Information](index=1&type=section&id=IV.%20Risk%20Warning%20and%20Other%20Related%20Information) The company advises investors that this performance forecast is based on preliminary estimates, and the final financial data will be subject to the 2025 semi-annual report, urging caution regarding investment risks - This performance forecast represents preliminary data estimated by the company's finance department and is not the final result[5](index=5&type=chunk) - The final accurate financial data will be disclosed in the company's 2025 semi-annual report, reminding investors to be aware of investment risks[6](index=6&type=chunk)

New Stock Issuance - Shanda Electric (Stock Code: 301609) issued at a price of 14.66[1] - Jiyuan Group (Stock Code: 732262) issued at a price of 10.88[1] Market Alerts - Jichuan Pharmaceutical (Stock Code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - The last trading day for Tuisan Jinguang (Stock Code: 600190) is July 14, 2025, with 4 trading days remaining[1] - The last trading day for Tuisan Jinjing (Stock Code: 900952) is also July 14, 2025, with 4 trading days remaining[1] Abnormal Fluctuations - *ST Zitian (Stock Code: 300280) reported severe abnormal fluctuations on July 10, 2025[1] - *ST Yushun (Stock Code: 002289) reported abnormal fluctuations on July 11, 2025[1] Other Notable Announcements - Longyuan Green Energy (Stock Code: 603185) announced on July 11, 2025[1] - Kedi Pharmaceutical (Stock Code: 000590) announced on July 14, 2025[1]

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the Chinese medicine sector [6]. Core Insights - The Chinese medicine sector saw a 1.08% increase last week, with the overall pharmaceutical sector experiencing a general upward trend [2]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.86X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.31X, also showing a minor rise [3]. - The market for Chinese medicinal materials is currently in a low season, with a slight decline in price indices due to increased rainfall in southern regions [4]. - As of July 12, 2025, three out of five listed companies in the Chinese medicine industry reported positive net profit growth, with the lowest growth rate at 24.3% [5]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6451.72 points, up 1.08% last week, while the overall pharmaceutical index rose by 1.82% [2][17]. Valuation - The PE ratio (ttm) for the Chinese medicine sector is 27.86X, up 0.29X week-on-week, with a one-year maximum of 30.13X and a minimum of 22.58X. The PB ratio (lf) is 2.31X, up 0.03X, with a one-year maximum of 2.65X and a minimum of 1.99X [3][19]. Industry Trends - The Chinese medicine sector is entering the mid-year reporting season, with a focus on performance metrics such as inventory and accounts receivable [5]. - The report highlights three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, indicating potential growth areas within the sector [6][9]. Investment Recommendations - Recommended companies include those with strong R&D capabilities and unique products, as well as those less affected by price collection policies. Specific companies highlighted are Zhaoli Pharmaceutical, Pizaihuang, and Shouxiangu [10].

一、股票交易异常波动的情况 启迪药业集团股份公司（以下简称"公司"）股票（证券简称：启迪药业， 证券代码：000590）连续 3 个交易日（2025 年 7 月 9 日至 7 月 11 日）收盘价格 涨幅偏离值累计达到 28.14%，根据《深圳证券交易所股票上市规则》的有关规 定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 证券代码：000590 证券简称：启迪药业 公告编号：2025-022 启迪药业集团股份公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 针对公司股票交易异常波动，公司对有关事项进行了核查，并致函公司控股 股东启迪科技服务有限公司（以下简称"启迪科服"）等，有关核查情况如下： 大影响的未公开重大信息； 筹划阶段的重大事项； 在买卖公司股票的情形。 三、不存在应披露而未披露信息的说明 和巨潮资讯网（www.cninfo.com.cn），公司所有信息均以在上述指定媒体披露 的信息为准，请广大投资者理性投资，注意风险。 特此公告。 启迪药业集团股份公司 董事会 本公司董事会确认，公司目前没有任何根据《深圳证券交易所股票上市规则》 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-022 启迪药业集团股份公司 股票交易异常波动公告 三、不存在应披露而未披露信息的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 启迪药业集团股份公司（以下简称"公司"）股票（证券简称：启迪药业， 证券代码：000590）连续 3 个交易日（2025 年 7 月 9 日至 7 月 11 日）收盘价格 涨幅偏离值累计达到 28.14%，根据《深圳证券交易所股票上市规则》的有关规 定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票交易异常波动，公司对有关事项进行了核查，并致函公司控股 股东启迪科技服务有限公司（以下简称"启迪科服"）等，有关核查情况如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道可能或已经对本公司股票交易价格产生较 大影响的未公开重大信息； 3、公司目前经营情况及内外部经营环境未发生重大变化； 4、公司、控股股东不存在关于本公司应披露而未披露的重大事项，或处于 筹划阶段的重大事项； 5、股 ...

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

Market Overview - A-shares experienced a collective rise on July 10, with the Shanghai Composite Index surpassing the 3500-point mark, closing at 3509.68 points, up 0.48% [1] - The Shenzhen Component Index rose 0.47% to close at 10631.13 points, while the ChiNext Index increased by 0.22% to 2189.58 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 149.42 billion yuan, a slight decrease of 11 billion yuan compared to the previous day [1] Sector Performance - The majority of industry sectors saw gains, with real estate development, engineering consulting services, real estate services, cement and building materials, coal, small metals, diversified finance, and steel industries leading the increases [1] - Conversely, the jewelry, shipbuilding, and manufacturing sectors experienced declines [1] Stock Movement - A total of 2947 stocks rose, with 69 hitting the daily limit up, while 2279 stocks fell, with 14 hitting the daily limit down [1] - The market showed signs of volatility, with significant fluctuations observed during the trading day, particularly in blue-chip stocks such as banks, insurance, and real estate [1] Investment Trends - Market focus on sectors experiencing a turnaround, particularly in photovoltaic, lithium battery, and real estate concepts, with significant price increases in silicon wafer prices ranging from 8% to 11.7% due to upstream silicon material price hikes [2] - Despite positive technical indicators, including a bullish engulfing pattern in the Shanghai Composite Index, the overall buying strength remains insufficient, indicating caution in stock selection is necessary [2] Company Spotlight - Xiangguo's stock performance was notable, with 86 out of 147 stocks rising, including Qidi Pharmaceutical, which hit the daily limit up after a previous gain of over 9% [3] - Qidi Pharmaceutical's main business includes "Guhang Yangshengjing" series products and traditional Chinese medicine, reporting a net profit of -16.26 million yuan for Q1 2025, a year-on-year decline of 96.23% [3] - The company is preparing for a potential change in control due to the auction of 24.47% of shares held by its controlling shareholder, and it has signed a strategic cooperation agreement to develop a traditional Chinese medicine health and wellness tourism base [3]

Market Overview - On July 9, the A-share market experienced a pullback after an initial rise, with the Shanghai Composite Index losing its earlier gains at the 3500-point mark, closing down 0.13% at 3493.05 points [1] - The Shenzhen Component Index fell 0.06% to close at 10581.80 points, while the ChiNext Index rose 0.16% to 2184.67 points [1] - Total trading volume in the Shanghai and Shenzhen markets reached 150.52 billion yuan, an increase of 51.2 billion yuan compared to the previous day [1] Sector Performance - The market saw more sectors decline than rise, with multi-financial, engineering consulting services, cultural media, medical services, and banking sectors showing the most significant gains [1] - Conversely, the insurance, small metals, precious metals, shipbuilding, and wind power equipment sectors experienced the largest declines [1] Individual Stock Performance - A total of 1856 stocks rose, with 61 hitting the daily limit, while 3327 stocks fell, with 6 hitting the lower limit [1] - Notable individual stock performances included Huayin Power and Jiuzi Tang hitting the daily limit, while Qidi Pharmaceutical rose over 9% [2] AI Education Sector - The knowledge payment sector saw the largest gains, driven by OpenAI's ChatGPT testing a new "learning together" mode, which enhances AI's role in education through interactive Q&A and personalized learning paths [2] - This technological breakthrough indicates a shift in AI education applications from simple knowledge retrieval to cognitive co-construction [2] Company Insights - Yueyang Xingchang, primarily engaged in the production of petroleum and petrochemical products, reported a net profit of 13.61 million yuan for Q1 2025, reflecting a year-on-year decline of 37% [3] - The company holds a 10% stake in the Jieyang Dongyue Chemical project, which is set to fully launch a 200,000-ton/year mixed waste plastic comprehensive utilization demonstration project, addressing waste plastic management challenges [3] - Yueyang Xingchang is recognized as the first domestic company to break the foreign monopoly on metallocene polypropylene catalyst technology, with its subsidiary Huizhou Litop currently ramping up production of qualified metallocene polypropylene products [3]

Investment Rating - The industry rating is maintained at "Overweight" [6] Core Insights - The Chinese medicine sector saw a 1.27% increase last week, lagging behind other pharmaceutical segments, with the overall pharmaceutical sector rising by 3.64% [2] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.57X, up 0.34X week-on-week, while the price-to-book (PB) ratio is 2.28X, also showing a slight increase [3] - The market for traditional Chinese medicine materials is experiencing increased supply but declining prices, with a 0.5% drop in the total price index last week [4] Summary by Sections Market Performance - The Chinese medicine sector's performance is weaker compared to other pharmaceutical segments, with notable companies like Jiuzi Tang and Zoli Pharmaceutical performing well, while others like Mayinglong and Dong'e Ejiao lag behind [2][15] Valuation - The current PE ratio of 27.57X places the sector at the 29.53% percentile since 2013, while the PB ratio of 2.28X is at the 5.37% percentile [3] Supply Chain Dynamics - The market for Chinese medicinal materials is characterized by increased production and declining prices, with a significant number of categories experiencing price drops [4] Policy Developments - The dual-track system for medical insurance and commercial insurance is being implemented, allowing for dynamic adjustments and submissions for inclusion in the basic medical insurance directory [5][6] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, highlighting companies with strong R&D capabilities and unique products [11][12][13]

Group 1 - The establishment of the first AIC chain master merger and acquisition equity investment fund, Ningbo Zhongying Xingxiang Fund, marks a new model of collaboration among five parties, including local government and industry leaders, with a total fund size of 1 billion yuan [1][2] - The fund aims to integrate resources within the automotive industry chain, focusing on high-end manufacturing and innovation through equity investments and capital operations [1][6] - The rise of Corporate Venture Capital (CVC) as a popular investment choice among Limited Partners (LPs) reflects a shift towards a "chain master + fund" model in the primary market, emphasizing the importance of chain master enterprises in driving industry growth [3][4][5] Group 2 - The current merger and acquisition trend is supported by numerous local government policies, with over 10 regions announcing initiatives to establish merger and acquisition funds [6][7] - The establishment of significant merger funds, such as the China Pacific Insurance's 30 billion yuan fund, indicates a growing focus on mergers and acquisitions as a strategic investment avenue [6][10] - The introduction of the "924 New Policy" by the China Securities Regulatory Commission encourages private equity funds to participate in mergers and acquisitions, potentially leading to a surge in such activities in the market [12][20][27] Group 3 - The increasing interest in mergers and acquisitions among investment institutions is evident, with many firms establishing dedicated merger departments to explore acquisition opportunities [23][24] - The average salary for merger managers in China can reach up to 500,000 yuan, highlighting the demand for talent in this emerging market [24][25] - The government's push to streamline the merger and acquisition process is expected to facilitate a more vibrant market for private equity involvement in corporate acquisitions [26][27]